In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron And Geisinger Get Ambitious In Next-Gen Genomics

Executive Summary

Regeneron and Geisinger’s new collaboration to identify genetic variants and apply that knowledge to drug discovery and patient care is pharma’s most ambitious effort to date to exploit next-generation genomics, but its impact on drug discovery productivity won’t be known for years.

Advertisement

Related Content

Regeneron On Genetics R&D: 'It's Our Oxygen'
A Researcher’s Hope For Sequencing: Rare Genetic Variants Yield New Drugs
Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond
The Sanofi Relationship Supports Regeneron’s FIBCO Strategy
BGI Touts Eventual Merck Deal

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004129

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel